During central nervous system autoimmunity, interactions between infiltrating immune cells and brain-resident cells are critical for disease progression and ultimately organ damage. Here, we demonstrate that local cross-talk between invading autoreactive T cells and auto-antigen-presenting myeloid cells within the central nervous system results in myeloid cell activation, which is crucial for disease progression during experimental autoimmune encephalomyelitis, the animal model of multiple sclerosis. This T cell-mediated licensing of central nervous system myeloid cells triggered astrocytic CCL2-release and promoted recruitment of inflammatory CCR2 + -monocytes, which are the main effectors of disease progression. By employing a cell-specific knockout model, we identify the nuclear receptor peroxisome proliferator-activated receptor c (PPARc) in myeloid cells as key regulator of their disease-determining interactions with autoreactive T cells and brain-resident cells, respectively. LysM-PPARc KO mice exhibited disease exacerbation during the effector phase of experimental autoimmune encephalomyelitis characterized by enhanced activation of central nervous system myeloid cells accompanied by pronounced local CCL2 production and inflammatory monocyte invasion, which finally resulted in increased demyelination and neuronal damage. Pharmacological PPARc activation decreased antigen-specific T cell-mediated licensing of central nervous system myeloid cells, reduced myeloid cell-mediated neurotoxicity and hence dampened central nervous system autoimmunity. Importantly, human monocytes derived from patients with multiple sclerosis clearly responded to PPARc-mediated control of proinflammatory activation and production of neurotoxic mediators. Furthermore, PPARc in human monocytes restricted their capacity to activate human astrocytes leading to dampened astrocytic CCL2 production. Together, interference with the disease-promoting cross-talk between central nervous system myeloid cells, autoreactive T cells and brain-resident cells represents a novel therapeutic approach that limits disease progression and lesion development during ongoing central nervous system autoimmunity.
Introduction
The central role of autoreactive encephalitogenic CD4 + T cells has clearly been demonstrated in the animal model of multiple sclerosis experimental autoimmune encephalomyelitis (EAE) as CNS autoimmunity can be elicited by adoptive transfer of autoreactive myelin oligodendrocyte glycoprotein (MOG)-specific CD4 + T cells (Stinissen et al., 1998) . These autoreactive CD4 + T cells are primed in the periphery within lymphatic tissues, migrate across the blood-brain barrier, and initiate autoimmune inflammation upon local reactivation by antigen-presenting cells (Reboldi et al., 2009) . Besides encephalitogenic T cells, myeloid cells are recruited into the CNS and can outnumber lymphocytes in acute multiple sclerosis lesions by at least 10-20 times (Prineas and Graham, 1981; Barnett et al., 2006) . During the last years, it became evident that CNS-infiltrating myeloid cells substantially contribute to local inflammatory processes as well as demyelination and axonal damage in multiple sclerosis and EAE (Geissmann et al., 2003; Lassmann, 2004; Mildner et al., 2009) . Recent studies further revealed that the subpopulation of inflammatory CCR2 + Ly-6C hi monocytes (Geissmann et al., 2003) amplifies the effector phase of CNS autoimmunity (Mildner et al., 2009) and that in vivo depletion of this subpopulation reduces disease severity (Tran et al., 1998) . Moreover, CNS-resident microglial cells can also contribute to CNS inflammation during EAE . However, the mechanisms driving myeloid cell activation during sterile autoimmunity induced by autoreactive T cells have not been resolved. Similarly, the cell-intrinsic factors that regulate responsiveness of myeloid cells towards such activation remained elusive. A potent regulator of macrophage activation is the nuclear receptor peroxisome proliferator-activated receptor (PPAR), a ligand-activated transcription factor that mediates a broad range of anti-inflammatory effects (Ricote et al., 1998; Clark et al., 2000; Storer et al., 2005; Klotz et al., 2007) . PPAR in myeloid cells acts by interference with NFB-target genes through a transrepression mechanism mediated by ligand-induced stabilization of the NCoR co-repressor complex at the promoter sites of pro-inflammatory genes such as inducible nitric oxide synthase or tumour necrosis factor (TNF) (Glass and Ogawa, 2006; Straus and Glass, 2007) .
Interestingly, peripheral blood mononuclear cells from patients with multiple sclerosis exhibited strongly decreased PPAR expression levels when compared with healthy controls (Klotz et al., 2005 ). As we have previously shown that ablation of PPAR expression in dendritic cells increases their capacity to prime naïve CD4 + T cells (Klotz et al., 2007) , we reasoned that PPAR may serve as a cell-intrinsic regulator of myeloid cell activity, and hence, that diminished PPAR activity in myeloid cells may critically contribute to CNS autoimmunity. In this study, we therefore addressed the question whether PPAR limits myeloid cell activation during CNS autoimmunity and thus restricts local innate immune responses during autoimmune inflammation in the CNS.
Materials and methods

Mice
Mice were bred and maintained under specific pathogen-free conditions at the Haus fü r Experimentelle Therapie, University of Bonn and used for experiments at 7-12 weeks of age. C57BL/6 mice and congenic C57BL/6 (CD45.1) mice were purchased from Charles River Laboratories. PPAR fl/fl mice were obtained from Jackson
Laboratories. Mice with a conditional PPAR knockout in myeloid cells (i.e. LysM-PPAR KO mice) were generated by crossing PPAR fl/fl mice with LysM-Cre transgenic mice, which express the Cre recombinase under control of the murine M lysozyme gene in monocytes/macrophages, microglia and neutrophils (Clausen et al., 1999) (Supplementary Fig. 1 ). To analyse recombination efficiency, LysM-Cre mice were crossed to R26-eYFP fl/wt mice ( Fig. 1A and Supplementary Fig. 1A ). Mice with a conditional knockout of PPAR in CNS-resident cells of neuroectodermal origin, i.e. neurons, astrocytes and oligodendrocytes, were generated by crossing PPAR fl/fl mice with Nestin-Cre transgenic mice (Tronche et al., 1999) ( Supplementary Fig. 3 ). Lines were backcrossed onto the C57BL/6 background for at least 10 generations. Genotyping of mice was performed by amplifying a portion of the particular gene from tail DNA. MHC-II-restricted T cell receptor-transgenic 2D2 mice specific for the myelin oligodendrocyte glycoprotein ) peptide and ovalbumin (OVA)-specific T cell receptor-transgenic OT-II mice were used (Bettelli et al., 2003) . All animal experiments were performed according to the guidelines of the animal ethics committee and were approved by the government authorities of Nordrhein-Westfalen, Germany. Nestin-PPAR WT (n = 6) and Nestin-PPAR KO mice (n = 6) and disease course was monitored. The mean clinical score AE SEM of one representative experiment out of four is shown. *P 5 0.05; **P 5 0.01; ***P 5 0.001. iNOS = inducible nitric oxide.
Cell culture
For preparation of mixed glial cultures, the cerebrum from post-natal Days 1-5 LysM-PPAR KO and LysM-PPAR WT or C57BL/6 mice was stripped of meninges. The cortices were mechanically dissociated as described previously , seeded into culture flasks in Dulbecco's Modified Eagle's Medium supplemented with 10% foetal calf serum, 50 mM b-mercaptoethanol, 2 mM L-glutamine, 1% nonessential amino acids, 10 5 U penicillin and 0.1 g/l streptomycin. After 2 weeks, microglial cells were harvested by vigorously tapping the flasks, the remaining astrocytes were used for experiments where indicated. Primary neuronal cultures were prepared from hippocampi of C57BL/6 mice embryos (embryonic Day15-16). Hippocampi were isolated, dispersed mechanically and seeded on 4-well chamber culture dishes, which were pretreated with 0.01 mg/ml poly-L-ornithine and 10 mg/ml laminin. The cells were cultured in basal medium Eagle supplemented with 2% B-27 supplement (Gibco-BRL, Invitrogen), 1% glucose (Sigma), and 1% foetal calf serum. Cells were cultured for 4 days to obtain morphologically mature neurons. Then, neurons were co-cultured with microglial cells.
Bone marrow-derived macrophages were generated as described previously (Racoosin and Swanson, 1989) . For PPAR-activation in microglia or bone marrow-derived macrophages, 10 mM pioglitazone (Axxora) was added for 7 days prior to stimulation. Bone marrow-derived macrophages were stimulated with 100 ng/ml lipopolysaccharide (LPS) (Sigma) and 10 ng/ml IFN (eBioscience); primary microglia and primary astrocytes were stimulated with 1 mg/ml LPS and 10 ng/ml IFN.
MOG 35-55 -transgenic (2D2) or OVA 323-33 -transgenic (OT-II) CD4 + T cells were isolated from spleen and lymph nodes by immunomagnetic separation using CD4-MACS beads (Miltenyi Biotec) according to the manufacturer's protocol. Cells were activated with plate-bound 4 mg/ml CD3 antibody (Clone: 145-2C11) and 4 mg/ml CD28 antibody (Clone: 37.51; eBioscience) for 72 h. Human monocytes were differentiated into macrophages as described (Schwab et al., 2008) . Written consent was obtained from all donors and blood sampling was approved by the local ethics committee and was performed according to the Declaration of Helsinki. Briefly, after peripheral blood mononuclear cells isolation from healthy volunteers and patients with multiple sclerosis, monocytes were selected by adhesion to plastic flasks for 1 h in X-vivo medium (density 2-10 Â 10 7 per 75 cm 2 flask). Then, cells were washed thoroughly and adherent monocytes were cultured in Roswell Park Memorial Institute medium (RPMI) supplemented with 10% foetal calf serum in the presence of 100 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF) (Peprotech) and 10 ng/ml macrophage colony-stimulating factor (M-CSF) (R&D Systems) in the presence or absence of 10 mM rosiglitazone (Enzo Life Sciences). Every other day, cytokines and rosiglitazone were freshly added. For analysis of surface marker expression and cytokine production, monocytes were stimulated with 1 mg/ml LPS for 24 h.
THP-1 cells were cultured in RPMI supplemented with 10% foetal calf serum. The human astrocytoma cell line U251 MG was cultured in minimum essential medium Eagle supplemented with 2 mM L-glutamine, and Earle's balanced salt solution adjusted to contain 1.5 g/l sodium bicarbonate, 0.1 mM non-essential amino acids and 1.0 mM sodium pyruvate and 10% foetal bovine serum.
Human-induced pluripotent stem cell derivation and validation is described elsewhere (Koch et al., 2011) . Differentiation of induced pluripotent stem cells into long-term neuroepithelial stem cells was performed following an established protocol (Koch et al., 2009 
Induction of experimental autoimmune encephalomyelitis
For active immunization, EAE was induced as described previously (Klotz et al., 2009) . For adoptive transfer EAE, mice were immunized with 50 mg MOG 35-55 peptide (Biotrend) emulsified in complete Freund's adjuvant (CFA) subcutaneously in the flank. After 10 days, splenic cells were isolated and cultured for 72 h in the presence of 20 mg/ml MOG 35-55 (Pineda) and 20 ng/ml IL-12 (R&D Systems). Cells (8 Â 10 6 ) were injected intraperitoneally into recipient mice, which also received 100 ng Bordetella pertussis toxin (Sigma) on Days 0 and 2 after adoptive transfer. Clinical assessment of EAE was performed daily using a scale ranging from 0 to 8: 0, no paralysis; 1, limp tail; 2, ataxia or unilateral hind limb paresis; 3, severe unilateral or weak bilateral hind limb paresis; 4, severe bilateral hind limb paresis; 5, complete bilateral hind limb plegia; 6, complete bilateral hind limb plegia and partial forelimb paresis; 7, severe tetraparesis/plegia; and 8, moribund/dead animals.
Oral treatment with pioglitazone
Mice were treated daily with 30 mg/kg body weight pioglitazone (Actos; Takeda Pharmaceuticals) suspended in 0.5% carboxymethylcellulose by oral gavage. Control mice received the vehicle only.
Histology
For immunohistological analysis, the CNS of EAE-diseased mice was perfused on Day 35 post immunization with Gey's balanced salt solution and heparin (Ratiopharm) and afterwards fixed in 4% paraformaldehyde. The spinal cord was isolated and immunohistochemistry was performed as described previously (Prinz et al., 2006 (Prinz et al., , 2008 (Bruhl et al., 2007; Mildner et al., 2009) . Specific depletion of inflammatory monocytes was monitored in the blood 8 h after the first injection.
In-vivo monocyte differentiation experiments
For in vivo labelling of circulating Ly-6C hi inflammatory monocytes during EAE, mice were treated as described before (Getts et al., 2008 
Isolation of central nervous system mononuclear cells
For mononuclear cell isolation, mice were anaesthetized with Avertin (Sigma), perfused with Gey's balanced salt solution and heparin, and brains and spinal cords were removed carefully. Tissue was mechanically dissected and digested with 1 mg/ml collagenase A (Sigma) in phosphate-buffered saline for 30 min at 37 C while shaking. The tissue was homogenized, washed and resuspended in 30% isotonic Percoll Õ , which was underlayered with 37 and 70% Percoll Õ . After gradient centrifugation, mononuclear cells were collected from the 30:37% and the 37:70% interface, washed extensively with phosphate-buffered saline, and analysed by flow cytometry.
Detection of nitric oxide, TNFa, IL-6 and CCL2
To evaluate nitric oxide production, nitrite concentrations were measured in the supernatants of cells after 48 h using the Griess Reagent (Invitrogen) according to the manufacturer's protocol. Release of IL-6, TNF and CCL2 in supernatants was quantified by ELISA after 24 and 48 h, respectively, according to the manufacturer's recommendation.
Determination of microglial neurotoxicity
Pioglitazone-treated or untreated primary microglia were harvested and stimulated with 1 mg/ml LPS + 10 ng/ml IFN. After 48 h, microglia were resuspended in neuronal medium without LPS and IFN and added to primary neurons at a ratio of 1:5 (microglia:neurons). After 24 h, immunohistological staining of neurons and analysis of relative neuronal neurite density was performed as previously described .
Flow cytometry
Surface marker staining was performed as described previously, using a BDCanto II (BD Biosciences) (Burgdorf et al., 2007) . For intracellular IFN and IL-17A staining, T cells were isolated from the CNS of EAE mice and restimulated ex vivo for 4 h with 5 ng/ml PMA and 200 ng/ml ionomycin in the presence of monensin and brefeldin A (eBioscience). Staining was performed using the BD Cytofix/ Cytoperm TM Fixation/Permeabilization Solution Kit (BD Bioscience)
according to the manufacturer's protocol. Results were analysed with FlowJo software (Tree Star).
Antibodies
Fluorochrome-labelled antibodies against murine CD3, CD4, CD8, CD11b, CD11c, CD40, CD45, CD45.1, CD45.2, F4/80, MHC-II, Ly-6C, Ly-6G, IL-17A, TNF and IFN for flow-cytometric analysis were obtained from eBioscience and BD Bioscience. Antibodies against human CD40, CD54, CD80, CD86 and HLA-DR were purchased from Biolegend and Miltenyi Biotec. Antibodies for ELISA (murine and human, respectively, TNF, IL-6 and CCL2) were obtained from Ebioscience and R&D Systems.
Quantitative real-time reverse transcriptase polymerase chain reaction 
Statistics
All data are expressed as mean AE SEM. Statistical analysis was performed using unpaired Student's t-test for all experiments except for EAE experiments, where we used the ANOVA plus Bonferroni test; P 5 0.05 were considered significant; P 5 0.01 were considered highly significant.
Results
Cell-intrinsic function of PPARc in myeloid cells during the effector phase of experimental autoimmune encephalomyelitis
Previously, we have shown that PPAR in CD4 + T cells controls development of T H 17 differentiation and T H 17-dependent induction of CNS autoimmunity (Klotz et al., 2007) . The effect of PPAR-ablation in T cells caused earlier disease onset but not aggravation of disease during the effector phase, which suggested that autoreactive CD4 + T cells mainly contributed to disease initiation but were not the critical mediators of local autoimmune damage. Therefore, we wondered whether other immune cells were critically involved in disease progression. To address this question, we generated myeloid cell-specific PPAR knockout mice by crossing LysM-Cre mice with transgenic mice carrying loxP sites within the PPAR gene (LysM-PPAR KO ). In order to quantify recombination efficiency, we crossed LysM-Cre mice with R26-eYFP fl/WT reporter mice and assessed YFP expression in immune cells by flow cytometry. As shown in Fig. 1A and Supplementary Fig. 1 , LysM-Cre mice exhibited high recombination-efficiency in monocytes, macrophages and granulocytes, and lower recombination efficiency in CNS-ex vivoderived adult microglia, whereas dendritic cells, T cells, and B cells were not affected [ Supplementary Fig. 1 and Clausen et al. (1999) ]. Upon EAE induction by immunization with MOG 35-55 , LysM-PPAR KO mice compared with wild-type mice showed a similar development of disease severity during the T cell-mediated induction phase (Fig. 1B) . Instead, LysM-PPAR KO mice exhibited a significantly aggravated disease course during the effector phase beginning at Day 15 (Fig. 1B ) and histopathological analysis of the spinal cords from LysM-PPAR KO mice during the effector phase at Day 35 after disease induction revealed exacerbated demyelination and axonal damage (Fig. 1C) . At this time point, CNS infiltration by macrophages and T cells was significantly increased (Fig. 1D ). Similar to findings in inflammatory brain lesions in patients with multiple sclerosis (Bruck et al., 1995; Barnett et al., 2006) , we found a clear predominance of macrophages over T cells in LysM-PPAR KO mice (Fig. 1D) . Augmented disease severity during the effector phase in LysM-PPAR KO mice was mirrored by an increased inflammatory milieu within the CNS characterized by enhanced expression of pro-inflammatory mediators and chemokines involved in immune cell recruitment ( Fig. 1E and F) . Hence, in the absence of the cell-intrinsic regulatory function of PPAR, myeloid cells facilitate immune cell recruitment and generation of a pro-inflammatory milieu, which contributes to enhanced demyelination and neuronal damage. As expected, pharmacological PPAR activation by the synthetic agonist pioglitazone not only ameliorated the disease course (Niino et al., 2001; Klotz et al., 2009 ) but also attenuated local pro-inflammatory responses and eventually CNS damage ( Supplementary Fig. 3 ).
To exclude a role of PPAR in other CNS-resident cells during EAE, i.e. neurons, astrocytes and oligodendrocytes, we generated mice that lack PPAR in cells derived from neuronal and glial precursors [Nestin-PPAR KO mice; Supplementary Fig. 3 Fig. 3A and B) , consistent with results shown in Fig. 1C . We next investigated whether PPAR also influenced the activation status of these cells during EAE and determined expression of CD40 and MHC-II, molecules critical for interaction with autoreactive T cells and therefore involved in disease deterioration (Becher et al., 2001; Greter et al., 2005) . CNS-infiltrating macrophages and microglia in LysM-PPAR KO mice showed increased expression of CD40 ( Fig. 3C ) and MHC-II (Fig. 3D) . Thus, PPAR ablation in myeloid cells increases not only local myeloid cell numbers in the CNS but also enhances their activation status, which points to a so far unrecognized role of CNS-located myeloid cells during the effector phase of EAE.
PPARc controls T cell-mediated licensing of macrophages
We hypothesized that during EAE, myeloid cells in the CNS were activated locally by autoreactive T cells and that ablation of PPAR facilitated this activation step. This prompted us to test whether antigen-specific interaction with MOG-specific CD4 + T cells results in myeloid cell activation. Similar to the observation in vivo, we observed increased production of nitric oxide and TNF upon antigen-specific interaction of PPAR KO compared with PPAR WT bone marrow-derived macrophages with autoreactive MOG-specific effector 2D2 T cells (Fig. 4A ). Of note, no production of these neurotoxic mediators was observed when T cells did not see their cognate antigen (Fig. 4A) . On the other hand, pharmacological activation of PPAR in macrophages by the synthetic ligand pioglitazone suppressed production of proinflammatory mediators elicited by antigen-specific interaction with CD4 + T cells (Fig. 4B) .
Importantly, antigen-specific activation of macrophages was not restricted to 2D2 T cells, but was also observed when macrophages were co-cultured with OVA-specific effector OT-II T cells, which was similarly found to be modulated by PPAR activity in macrophages (Fig. 4C) . In addition to induction of proinflammatory mediators, antigen-specific interaction with either MOG-or OVA-specific CD4 + T cells elicited upregulation of the co-stimulatory molecule CD40 on macrophages (Fig. 4D ). This upregulation was also controlled by cell-intrinsic PPAR-activity, as it was enhanced in PPAR KO macrophages and reduced in PPAR-activated macrophages (Fig. 4D) . Together, these results indicate that encephalitogenic CD4 + T cells license myeloid cells upon antigen-specific interaction, which results in induced expression of effector molecules that drive CNS inflammation and organ damage (Hendriks et al., 2005) . Importantly, PPAR in macrophages controls this licensing step.
Based on these findings we next asked whether pharmacological PPAR-activation in vivo would also influence the functional outcome of myeloid cell cross-talk with disease-triggering T cells during the effector phase of EAE (Day 21). CNS macrophages and microglia of pioglitazone-treated mice exhibited reduced expression of CD40 and MHC-II compared with vehicle-treated mice (Fig. 4E) . Importantly, this reduction in CD40 and MHC-II expression on CNS-infiltrating macrophages by pioglitazone treatment was mediated by PPAR-activation directly in myeloid cells, because we did not observe such reduction in pioglitazone-treated LysM-PPAR KO mice (Fig. 4F) untreated PPAR WT or PPAR KO bone marrow-derived macrophages were co-cultured with pre-activated OT-II T cells in the presence of the specific antigen OVA (5 mg/ml) or the unrelated antigen MOG (5 mg/ml), and nitric oxide and TNF was determined as in (A). (D) CD40 expression on CD11b + cells was determined after 24 h by flow cytometry on bone marrow-derived macrophages co-cultured with activated 2D2 T cells or OT-II T cells in the presence of the cognate antigen or an unrelated antigen as in A-C, respectively. (E) Thirty milligram per kilogram body weight pioglitazone or vehicle only (carboxymethylcellulose, CMC) was administered daily by oral gavage to C57BL/6 wild-type mice and on Day 7 EAE was induced. On Day 21 after EAE-immunization, CD40 and MHC-II expression on CNS-macrophages and microglia was analysed by flow cytometry as described in Fig. 3 (n = 5 per group). (F) LysM-PPAR KO mice were orally treated with pioglitazone or vehicle only as described in (E), macrophages were isolated from the CNS during the effector phase (Day 21) and flow cytometrically analysed for CD40 and MHC-II expression (n = 4 per group). Numbers in histograms express mean MFI AE SEM; accompanying graphs depict mean percentage AE SEM.*P 5 0.05; **P 5 0.01; ***P 5 0.001.
that during EAE the chemokine CCL2 is responsible for CCR2 + immune cell-recruitment (Huang et al., 2001) . Interestingly, we observed that PPAR in myeloid cells regulated local CCL2 expression within the CNS during EAE, as LysM-PPAR KO EAE mice exhibited significantly enhanced CCL2-messenger RNA levels within the inflamed CNS, whereas PPAR activation during EAE resulted in reduced CCL2 expression levels within the CNS (Fig. 5A ). During CNS inflammation in multiple sclerosis and EAE, astrocytes have been shown to be the main source of CCL2 both in mice and humans (Van Der Voorn et al., 1999; Giraud et al., 2010) . We therefore wondered whether activated CNS myeloid cells might modulate astrocytic CCL2 production. In a first step, we exposed primary murine astrocytes to pre-activated PPAR WT or PPAR KO bone marrow-derived macrophages, and subsequently assessed CCL2 production. Activated macrophages themselves produced only low amounts of CCL2 (Fig. 5B ), but elicited substantial CCL2 production in co-cultured astrocytes (Fig. 5B) , whereas resting macrophages did not induce astrocytic CCL2 production (Fig. 5B) . Importantly, lack of PPAR in myeloid cells significantly augmented their capacity to elicit astrocytic CCL2 production (Fig. 5B) . Following this line further, we asked whether antigen-specific interaction with activated CD4 + T cells equally enables macrophages to evoke astrocytic CCL2 production, as the interaction with autoreactive T cells can be considered as more disease-relevant stimulus compared with LPS-stimulation.
Macrophages evoked substantial astrocytic CCL2 production selectively following antigen-specific interaction with CD4 + T cells (Fig. 5C ). With regard to the experimental setup, it is important to note that following interaction with effector CD4 + T cells, macrophages were purified prior to astrocyte co-culture. Moreover, activated CD4 + T cells themselves did not evoke astrocytic CCL2 production upon co-culture (Fig. 5C ). As observed before, lack of PPAR in macrophages augmented, whereas pharmacological PPAR activation reduced astrocytic CCL2 production (Fig. 5C ). Of note, we observed no relevant CCL2 production by either resting or activated T H 1 or T H 17 cells ( Supplementary Fig. 4A ), suggesting that autoreactive T cells during EAE are not a source of CCL2. To exclude altered astrocyte function in the CNS of LysM-PPAR KO mice, we determined CCL2 production by astrocytes isolated from LysM-PPAR KO mice or their wild-type littermates and did not observe any differences ( Supplementary Fig. 4B ). Together, these data suggest that CNS myeloid cells become activated upon antigen-specific interaction with autoreactive T cells and then engage in further cross-talk with astrocytes triggering astrocytic CCL2-production; this cross-talk is modulated by PPAR in myeloid cells. Based on these results we next addressed the question whether PPAR also influences the function of CCR2 + inflammatory monocytes during the effector phase of EAE. To address this experimentally, we depleted CCR2 + Ly-6C hi inflammatory monocytes phages were stimulated with LPS and IFN for 24 h (stim) or bone marrow-derived macrophages were prestimulated with LPS and IFN for 1 h, thoroughly washed, and subsequently co-cultured with unstimulated primary murine astrocytes at a ratio of 1:1 for 24 h. CCL2 secretion was measured by ELISA. ***Statistical significance between wild-type and knockout bone marrow-derived macrophages; ### Statistical significance between unstimulated astrocytes and co-culture groups (P 5 0.001). (C) Primary murine astrocytes were cultured either alone, with activated OT-II T cells, with unstimulated bone marrow-derived macrophages or with bone marrow-derived macrophages that had been pre-activated in co-culture with OT-II effector T cells in the presence of OVA 323-339 or MOG for 24 h. After T cell interaction, bone marrow-derived macrophages were purified and subsequently co-cultured with astrocytes for 24 h (ratio 2:1). CCL2 secretion was determined by ELISA. # Statistical significance between astrocytes alone and indicated co-culture groups; *Statistical significance within one particular co-culture group. (D-F) CCR2 + inflammatory monocytes were depleted during EAE in LysM-PPAR KO by repetitive injection of the CCR2 antibody MC-21 ( Supplementary Fig. 5 ) (Bruhl et al., 2007; Mildner et al., 2009) and determined its effect on disease progression. Depletion of CCR2 + cells not only ameliorated the EAE disease course, but also abolished the observed differences in disease severity between LysM-PPAR KO mice and their wild-type littermates (Fig. 5D) . Concomitantly, depletion resulted in reduced expression levels of pro-inflammatory mediators within the CNS and furthermore completely abrogated the differences in pro-inflammatory gene expression between LysM-PPAR KO and LysM-PPAR WT mice (Fig. 5E) . Importantly, depletion of CCR2 + cells during EAE nearly completely abrogated local CCL2 expression in the CNS indicating the existence of a self-perpetuating recruitment of CCL2-responsive cells at later stages of disease (Fig. 5E ). At the single cell level, PPAR KO macrophages from MC-21-treated animals still exhibited increased expression levels of MHC-II and CD40 (Fig. 5F ), suggesting that the antibody treatment did not alter the activation status of PPAR-ablated CNS-resident myeloid cells per se.
To more specifically address the relevance of PPAR in inflammatory monocytes during the effector phase of EAE we adoptively transferred PPAR KO exhibited a more aggravated effector phase, further pointing towards a monocyte-intrinsic effect of PPAR to control disease activity. Taken together, these results allow two important conclusions: first, local activation of CNS myeloid cells evokes astrocytic CCL2 production, which is then maintained by a sustained influx of inflammatory monocytes in a self-perpetuating fashion. Second, PPAR in myeloid cells controls both recruitment and activity of CCR2 + inflammatory monocytes as central driving force for progression of CNS autoimmunity during EAE.
Organ-protective role of PPARc in central nervous system-resident myeloid cells
Besides inflammatory monocytes, microglia cells also critically determine the extent of local inflammation and hence disease severity during the effector phase of EAE . Given the prominent function of inflammatory monocytes in our experiments we wondered whether these cells might acquire microglial features within the inflammatory CNS environment. Several reports demonstrated that under certain conditions, e.g. viral encephalitis, and blood-brain-barrier injury after irradiation (Getts et al., 2008; Mildner et al., 2008) , CNS-invading inflammatory monocytes can acquire a microglial phenotype. To follow the fate of inflammatory Ly-6C hi monocytes during EAE in vivo, we labelled Ly-6C hi monocytes using an in vivo clodronate-liposome-based bead labelling method as described previously (Getts et al., 2008) .
To this end, we injected FITC-labelled polystrene beads 12 h after depletion of monocytes from the blood by clodronate liposomes. This resulted in preferential labelling of Ly-6C hi monocytes in clodronate-liposome-treated mice but not in phosphate-buffered saline-liposome-treated mice ( Supplementary Fig. 7) . Already 12 h after labelling, we observed a distinct population of FITC-labelled inflammatory monocytes in the CNS of clodronate-liposome-treated EAE mice, demonstrating rapid recruitment during ongoing autoimmune inflammation ( Fig. 6A and B) . This experiment excluded extravasation of FITC-labelled beads into the inflamed CNS and subsequent uptake by resident microglial cells, because only very few labelled cells were found in the CNS of EAE mice that received phosphate-buffered saline-liposomes (Fig. 6A) . We subsequently analysed CD45 expression levels on FITC + cells, as CD45 is a reliable marker to distinguish macrophages from microglial cells (Getts et al., 2008) , and found that within the short time frame of 12 h investigated here, nearly 10% of FITC-labelled inflammatory monocytes in the CNS already exhibited a microglial phenotype ( Fig. 6A and B). We corroborated these results by an independent method, i.e. by transfer of CD45 hi CD45.2 + monocytes into EAE-diseased CD45.1 + hosts (Fig. 6C) . Again, we observed that $5% of all transferred CD45.2 + monocytes now expressed intermediate levels of CD45 12 h after transfer, thus exhibiting a microglial phenotype. Based on our results showing a critical role of PPAR in the control of myeloid cell-mediated aggravation of EAE during the effector phase, we next investigated whether PPAR also influences the organ damaging function of myeloid cells. Stimulation of macrophages and microglia resulted in production of TNF and nitric oxide ( Fig. 6D and E) , molecules that mediate neurotoxicity (Hendriks et al., 2005) . Indeed, pharmacological PPAR activation suppressed release of these mediators and likewise PPAR-ablated cells showed increased production of these molecules ( Fig. 6D and E). Consistent with a regulatory role of PPAR we found that in vivo PPAR activation induced an immune-regulatory phenotype in monocytes ( Supplementary Fig. 8A ) that is also referred to as alternative or M2 activation (Fairweather and Cihakova, 2009 ). Of note, a similar induction of an M2 phenotype could be achieved by PPAR activation in human monocytes ( Supplementary Fig. 8B ). Importantly, primary microglial cells also showed PPARmediated control of expression production of neurotoxic mediators ( Fig. 6D and E) , which had neuroprotective effects as assessed in a 24 h co-culture assay with primary neurons. PPAR activation in microglial cells preserved neurite density under inflammatory as well as non-inflammatory conditions, indicating a continuous role for PPAR-mediated control of microglial neurotoxicity (Fig. 6F) .
PPARc in human monocytes dampens pro-inflammatory responses and restricts induction of astrocytic CCL2 production
We next questioned whether human monocytes would also be responsive to PPAR activation. In a first approach we analysed the inflammatory response of THP-1 cells, a well-characterized human monocytic cell line, following pharmacological PPAR activation with rosiglitazone. We observed that upon LPS stimulation, rosiglitazone-treated THP-1 cells expressed significantly reduced levels of CD40, CD80 and HLA-DR (Fig. 7A ) and produced significantly decreased amounts of TNF (Fig. 7B ). This prompted us to investigate whether PPAR activation in primary human monocytes differentiated from peripheral blood mononuclear cells of healthy donors would also result in dampened inflammatory responses upon stimulation. Indeed, we observed that PPAR activation resulted in significantly impaired upregulation of the activation markers CD40, CD54, CD80, CD86 and HLA-DR (Fig. 7C) as well as decreased production of the proinflammatory cytokines TNF and IL-6 upon pro-inflammatory stimulation (Fig 7D) . With regard to the development of novel therapies for patients with multiple sclerosis, we next asked whether monocytes from patients with multiple sclerosis were also responsive towards PPAR-mediated control of proinflammatory activation. Importantly, rosiglitazone-treated monocytes from patients with multiple sclerosis also exhibited significantly reduced upregulation of both activation markers (Fig. 7E ) and proinflammatory cytokines (Fig. 7F) , following inflammatory stimulation. Additionally, we observed that human monocytes can be stimulated by pre-activated human Jurkat T cells, which was assessed by production of TNF and IL-6 ( Supplementary Fig. 9 ), and PPAR activation in human monocytes by rosiglitazone limited such activation.
Since we observed that activated murine macrophages elicit CCL2 production in astrocytes (Fig. 5B and C) and that this CCL2 induction was limited upon PPAR activation in macrophages, we next questioned whether activated human monocytes were also able to induce CCL2 production by human astrocytes.
To this end, we set up a co-culture system of primary human monocytes and human-induced pluripotent stem cell-derived astrocytes ( Supplementary Fig. 10 ). Also in the human system, preactivated monocytes both from healthy donors and patients with multiple sclerosis elicited substantial CCL2 production by astrocytes (Fig. 7G) . Importantly, PPAR activation in human monocytes significantly restricted this induction of astrocytic CCL2 production (Fig. 7G) . These results could be corroborated using a human astrocytic cell line (U251 MG; Supplementary Fig. 11 ). Together, these data indicate that also in humans, PPAR modulates the activation status of myeloid cells from both patients with multiple sclerosis and controls, and that the interaction between human astrocytes and activated myeloid cells can elicit substantial astrocytic CCL2 production.
In summary, our data reveal a crucial role of PPAR in myeloid cells and in inflammatory monocytes as key players during the effector phase of EAE. PPAR in myeloid cells controls the outcome of T cell-induced cross-talk among CNS resident cells, which also dampens their innate effector functions resulting in reduced neuro-inflammation and amelioration of inflammation-induced neurotoxicity (Fig. 8) .
Discussion
It is generally believed that CNS autoimmunity is a process promoted by autoreactive T cells (Stinissen et al., 1998) . However, within inflammatory multiple sclerosis lesions or in the CNS of EAE mice, myeloid cells by far outnumber T cells and contribute to disease progression (Bruck et al., 1995; Barnett et al., 2006; Mildner et al., 2009 ). Yet it is not clear why CNS myeloid cells contribute to an autoimmune disease process that occurs in the absence of innate inflammatory stimulation. In this study, we made use of a cell-type specific ablation of the anti-inflammatory transcription factor PPAR to study the contribution of myeloid cells to disease progression after encephalitogenic T cell invasion in CNS autoimmunity. These experiments revealed a hitherto unrecognized role of myeloid cells in driving progression of T cellinitiated CNS autoimmunity characterized by the following sequence of events: within the CNS, antigen-presenting myeloid cells were initially licensed by autoreactive T cells upon cognate antigen-recognition. The local inflammatory response elicited by this interaction during the early stages of CNS autoimmunity evokes CCL2 production through local cross-talk with astrocytes followed by recruitment of CCR2 + inflammatory monocytes into the CNS, which then function as the main effectors of organ damage. Furthermore we provide evidence that the nuclear receptor PPAR in myeloid cells serves as a homeostatic control switch acting at several important steps of myeloid cell-driven In the context of CNS autoimmunity, it was suggested that innate inflammatory stimuli acting on myeloid cells may participate in induction and aggravation of disease (Prinz et al., 2006; Kierdorf et al., 2010) . However, this fails to explain how CNS autoimmunity can be induced by adoptive transfer of autoreactive effector CD4 + T cells alone in the absence of additional innate inflammatory activation. Here, we provide experimental evidence indicating that auto-antigen presentation by local myeloid cells in the CNS to infiltrating encephalitogenic T cells is crucial for myeloid cell activation and hence, propagation of CNS autoimmunity. This antigen-specific local cross-talk may represent a so far unrecognized turning point between T cell-driven induction and myeloid cell-driven effector phase of CNS autoimmunity. While our report is the first to describe antigen-specific but myeloid cell-mediated propagation of autoimmunity in the CNS, a similar key role for antigen-presenting cell licensing was made in autoimmune kidney disease. In a model of T cell-mediated kidney damage, initial cross-talk between CD4 + T cells and local antigen-presenting dendritic cells within the target organ was required for recruitment of autoreactive CD8 + T cells that then initiated progression of organ damage (Heymann et al., 2009 It is important to note that in this system, transferred MOG-specific T cells were the only possible triggers of local myeloid cell activation. However, it is not possible to dissect whether encephalitogenic T cells are still required to sustain this process or alternatively, whether once initiated, myeloid cells function independently to drive immune cell recruitment and organ damage.
In the context of CNS autoimmunity, the identity of signals provided by T cells during this antigen-specific licensing step remains elusive, however, several molecules, e.g. CD40L, granulocyte-macrophage colony-stimulating factor and IFN have been identified as crucial mediators of T cell-mediated activation of antigen-presenting cells such as dendritic cells, macrophages and microglial cells (Koya et al., 2003; Koguchi et al., 2007; Min et al., 2010) . Especially, CD40-CD40L interaction represents an interesting candidate in this context, as preformed CD40L exists in secretory lysosomes of effector CD4 + T cells and is quickly expressed in an antigen-specific fashion (Koguchi et al., 2007) . In support of this hypothesis, we observed that the strength of human monocyte activation by human Jurkat T cells correlated to CD40L expression-levels on the T cell side (data not shown); however, it has to be pointed out that this setup did not involve antigen-specific interaction of monocytes and T cells. The general importance of CD40-CD40L interaction in CNS autoimmunity has convincingly been demonstrated (Becher et al., 2001; Chen et al., 2006) , and microglial CD40 expression is essential for their full activation within the CNS, resulting in further effector T cell recruitment and expansion and hence disease progression (Ponomarev et al., 2006) . Myeloid cell-dependent propagation of autoimmune CNS disease comprised several key aspects: first, autoantigen-specific cross-talk with autoreactive T cells caused myeloid cell expression of molecules known to promote further T cell stimulation, such as CD40 and MHC class II. These molecules promote T cell-mediated CNS pathology (Becher et al., 2001) and it is tempting to Figure 7 Continued (G) Rosiglitazone-treated or untreated monocytes from healthy donors or from patients with multiple sclerosis (MS) were pre-stimulated for 48 h with LPS and IFN thoroughly washed, and co-cultured with human iPS cell-derived astrocytes at a ratio of 2:1 (monocytes:astrocytes) for 24 h. CCL2 production AE SEM was determined by ELISA. # Statistical significance between astrocytes alone and co-culture group; *Statistical significance within co-culture group. One representative experiment from seven healthy donors and five patients with multiple sclerosis is depicted. *P 5 0.05; **P 5 0.01; ***P 5 0.001; # P 5 0.05; ### P 5 0.001. w/o = without. speculate that they may also further accentuate myeloid cell activation in a self-perpetuating circle. Second, activated myeloid cells induce in a further cross-talk chemokine expression, particularly CCL2, by astrocytes which is known to trigger recruitment of inflammatory CCR2 + monocytes into the CNS the key cell population that drives disease progression during the effector phase of EAE (Mildner et al., 2009) . Both, during EAE and in acute inflammatory multiple sclerosis lesions, astrocytes seem to be the main source of CCL2, whereas myeloid cells and T cells do not produce much CCL2 under these conditions (Van Der Voorn et al., 1999; Giraud et al., 2010) . Although we cannot formally rule out that myeloid cells or activated T cells contribute to local CCL2 production in vivo, we observed that astrocytic CCL2 production strongly exceeded CCL2 production by myeloid cells and CD4 + T cells in vitro. We now provide evidence for the first time that local interaction between activated myeloid cells and astrocytes is the key trigger for astrocytic CCL2 production. Importantly, this myeloid cell-induced astrocytic CCL2 production required preactivation of myeloid cells e.g. by antigen-specific interaction with CD4 + effector T cells, which indicates that this licensing step facilitates cross-talk of myeloid cells with other cells involved in CNS autoimmunity. The exact mechanisms governing myeloid cell-induced expression of CCL2 by astrocytes remain unclear but it is important to note that astrocytic chemokine production was modulated by PPAR activity in myeloid cells. An important question raised by our results is whether endogenous PPAR ligands might be relevant for continuous protection from inappropriate myeloid cell licensing under physiological conditions. This hypothesis is supported by the fact that cell-type specific ablation of PPAR augmented disease progression, indicating that endogenous ligands were involved in PPAR-mediated control of myeloid cell sensitivity. In other words, a particular baseline activity of PPAR provided by local production of endogenous PPAR ligands might serve as endogenous homeostasis signal preventing inappropriate immune activation and perhaps even contribute to the immune privileged state of the CNS. In support of this hypothesis, it has been observed that ablation of the enzyme involved in the production of several important PPAR ligands, i.e. 12,15-lipoxygenase, resulted in enhanced CNS autoimmunity (Emerson and LeVine, 2004) , whereas oral treatment with its substrate linoleic acid ameliorated clinical and histopathological signs of EAE (Harbige et al., 1995) . In the CNS, IL-4 stimulation induces production of endogenous PPAR ligands in microglial cells (Yang et al., 2002; Ponomarev et al., 2007) and high IL-4 levels are associated with resolution of CNS inflammation during EAE and in patients with multiple sclerosis (Falcone et al., 1998; Franciotta et al., 2000) . IL-4 is also known to induce alternative activation of macrophages or M2 macrophages, and these M2 macrophages have a strong capacity to limit ongoing CNS autoimmunity (Butovsky et al., 2006; Weber et al., 2007) . Interestingly, phenotype and function of PPAR-activated myeloid cells during CNS autoimmunity are reminiscent of immunoregulatory macrophages. Following this line, we demonstrate that PPAR activation in mice also induced alternative activation of circulating and splenic monocytes ( Supplementary Fig. 8A ), and likewise of human monocytes as previously shown (Bouhlel et al., 2007 ; initiates production of inflammatory and neurotoxic mediators (1). Reciprocal antigen-specific interaction between myeloid cells and T cells may establish a self-amplifying circle of mutual activation (2). Activated myeloid cells elicit local CCL2 production by astrocytes (3), which results in recruitment of CCR2 + inflammatory monocytes into the CNS (4). Newly recruited inflammatory monocytes perpetuate local CCL2 production and further immune cell recruitment and inflammation ultimately leading to aggravation of neurotoxicity and enhanced demyelination (5).
(B) PPAR in myeloid cells controls T cell-mediated licensing (1) and decreases the ability of myeloid cells to re-stimulate encephalitogenic T cells (2), thereby attenuating proinflammatory cytokine and chemokine production (3) and hence inflammatory monocyte recruitment (4), ultimately resulting in decreased neurotoxicity and demyelination (5). Supplementary Fig. 8B ). It is therefore an intriguing concept that the local microenvironment as a source of endogenous PPAR-ligands may act as 'anti-danger' signal to influence the outcome of CNS autoimmunity by promoting alternative activation of myeloid cells. T cell-specific PPAR-ablation revealed a separate function of PPAR in CNS autoimmunity characterized by enhanced differentiation of PPAR KO T cells into T H 17 cells that accelerate disease induction but do not affect the disease activity during the effector phase. The strategy of cell-specific PPAR ablation allowed us to dissect the distinct and complementary roles of T cells and myeloid cells at the different disease stages. An important conclusion from our findings is that therapeutic approaches, which target myeloid cells, may be more effective for modulation of ongoing CNS autoimmunity in patients with multiple sclerosis than those targeting T cell responses. In patients with multiple sclerosis, we have previously shown that peripheral blood mononuclear cells exhibited decreased PPAR expression levels, and that PPAR activity inversely correlated with disease activity (Klotz et al., 2005) . It is not possible to determine whether lower PPAR expression levels are the consequence or cause of autoimmunity in these patients. However, in light of our findings presented here, these data suggest that in patients with multiple sclerosis, reduced PPAR activity in myeloid cells may facilitate disease exacerbation due to an intrinsically lowered threshold towards T cell-mediated licensing. Importantly, we demonstrate here that PPAR controls inflammatory activation of human monocytes and that this also holds true for monocytes from patients with multiple sclerosis. This indicates that myeloid cells from patients with multiple sclerosis can be targeted by PPAR activation, which might in turn contribute to correction of decreased PPAR activity observed in multiple sclerosis (Klotz et al., 2005) . Even more interestingly, we provide evidence that primary human monocytes elicit CCL2 secretion by human astrocytes, which can be modulated by PPAR in myeloid cells. This suggests that cross-talk between astrocytes and myeloid cells within the CNS, which results in CCL2-mediated immune cell recruitment, is also a feature of human CNS autoimmunity. Taken together, our data suggest that myeloid cells amplify the disease-inducing potential of encephalitogenic T cells and perpetuate progression of CNS autoimmunity following initial antigen-specific interaction. We identify PPAR in myeloid cells as critical factor in regulating such licensing and hence as a promising target for attenuating myeloid cell-mediated autoimmunity and ultimately organ damage.
